Investors, we're still at ph 1 with the exception of PD Vaxx (Ph 2) and we've been presented with effectiveness of all 4 clinical trials, the next milestone is data from these 84 patients. We need to give management little bit of breathing space as these trial takes time and has follow definite protocol and timeline. I've accumulated recently and further thinking of averaging down, however will wait, how things unfolds towards the end of June.
Ann: Imugene Presentation to Bell Potter Conference, page-71
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
